This educational content is a draft pending clinical review and has not been approved for patients. Do not treat it as final.
GLP-1 receptor agonist
Semaglutide
FDA-Approved moleculeCompounded form not FDA-approvedAn FDA-approved medication studied in large clinical trials. Here's what the research actually says — and where it stops.
Education only — not medical advice. No dosing or administration guidance. A licensed provider makes all clinical decisions.
What it is
Semaglutide is a prescription medication in a class of drugs called GLP-1 receptor agonists. It is FDA-approved, and under different brand names it is used in the management of type 2 diabetes and, separately, for chronic weight management in people who meet specific clinical criteria.
Chemically, it is a synthetic peptide designed to resemble GLP-1, a hormone the gut naturally releases after eating. Whether semaglutide is appropriate for any one person is a clinical decision made by a licensed provider after reviewing that person's full history.
How it works
After a meal, the gut releases a hormone called GLP-1. Semaglutide is designed to mimic that hormone and act on the same receptors in the body.
Through those receptors it influences signals related to appetite and the feeling of fullness, and it slows how quickly the stomach empties. Researchers describe these as the mechanisms most associated with its studied effects on appetite and blood-sugar regulation.
It does not act as a stimulant or directly “burn” fat. Its studied effects operate through appetite-regulation and metabolic signaling pathways.
What the research actually shows
Semaglutide carries our highest evidence tier: FDA-Approved. In practice that means it has been evaluated in large, randomized, controlled trials and reviewed by regulators for specific, defined uses — a higher bar than most compounds in this library meet.
Published trials have studied its effects on blood-sugar control in type 2 diabetes and on body weight in chronic weight management, in defined patient populations following defined study protocols.
We intentionally do not publish efficacy figures, outcome percentages, or comparisons on this page. Those belong in the cited primary sources and in a conversation with your provider, who can judge what the evidence means for your individual situation.
Honest about the limits
- FDA approval is for specific, defined uses. It does not mean a medication is appropriate, safe, or effective for everyone, or for goals outside what was studied.
- Trial populations, durations, and conditions may not resemble any given individual's situation.
- Documented side effects — commonly gastrointestinal, among others described in the official prescribing information — are part of the evidence and are weighed by a licensed provider, not by this page.
The part most brands leave out
What we don't know yet
- Long-term outcomes beyond the durations studied in trials are still being researched; very-long-term safety and effectiveness data continue to accumulate.
- How any benefits are sustained — or change — after stopping, and what the best long-term approach is, remain active areas of study.
- Individual response varies and is not fully predictable. Why some people respond differently, or experience more side effects, is not completely understood.
- Use for goals or populations outside the studied, approved indications is not established here and is a clinical judgment for a licensed provider, never a given.
Citations
[Citations to be added and verified by clinical team]
This is education, not medical advice.
Nothing on this page is a recommendation to use any treatment, and it contains no dosing or administration guidance. It does not establish a provider–patient relationship. A licensed provider makes every clinical decision.